TITLE

Target identification: A new target for treating progeria

AUTHOR(S)
Charlotte, Harrison
PUB. DATE
July 2013
SOURCE
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p506
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on a new therapeutic target for progeria, referencing a study by M. X. Ibrahim et al published in the May 16, 2013 issue of "Science."
ACCESSION #
88783755

 

Related Articles

  • DIY approach to drug discovery. Nowak, Rachel // New Scientist;7/19/2003, Vol. 179 Issue 2404, p21 

    Francis Collins, director of the National Human Genome Research Institute in Bathesda, Maryland announced a chemical genomics project that will allow academics to carry out the first stages of drug development as part of their existing research. The problem, he says, is that drug companies...

  • Research on Hutchinson-Gilford Progeria Syndrome. Warner, Huber R. // Journals of Gerontology Series A: Biological Sciences & Medical ;Aug2008, Vol. 63 Issue 8, p775 

    The author comments on the research concerning Hutchinson-Gilford Progeria Syndrome (HGPS). He argues that the ideal solution for the HGPS would be a total cure, although, numerous studies have reported that farnesyltransferase inhibitors reverse the morphological defects in HGPS. J. Hutchinson...

  • Old before their time. McPhee, A.T. // Current Science;2/20/98, Vol. 83 Issue 11, p10 

    Presents information on the effects of the Progeria disease in relation to an individual's experiences. Detailed information on the disease; Reference to Denny Sim, progeria sufferer; Comments from W. Ted Brown, geneticist. INSET: Death of a cell.

  • Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Columbaro, M.; Capanni, C.; Mattioli, E.; Novelli, G.; Parnaik, V.; Squarzoni, S.; Maraldi, N.; Lattanzi, G. // Cellular & Molecular Life Sciences;Nov2005, Vol. 62 Issue 22, p2669 

    Hutchinson-Gilford progeria (HGPS) is a premature aging syndrome associated with LMNA mutations. Progeria cells bearing the G608G LMNA mutation are characterized by accumulation of a mutated lamin A precursor (progerin), nuclear dysmorphism and chromatin disorganization. In cultured HGPS...

  • Aging: A new target in progeria. Swami, Meera // Nature Medicine;Jun2013, Vol. 19 Issue 6, p682 

    The article provides information on a study by Mohamed X. Ibrahim and his colleagues, which informs that premature aging disease progeria is therapeutically treated by targeting the enzyme isoprenylcysteine carboxyl methyltransferase (ICMT).

  • FDA Drug Approvals. Pipeline preview.  // Formulary;Dec2011, Vol. 46 Issue 12, p507 

    The article discusses research which the U.S. Food and Drug Administration conducted in 2011 on several drugs, including lluvien, vismodegib and apixaban, to determine whether they would be given approval for use.

  • Refining the Art of Antibody Production. DePalma, Angelo // Drug Discovery & Development;May2003, Vol. 6 Issue 5, p79 

    Reports on the growing popularity of using antibodies in drug discovery and therapeutics. Efforts in molecular engineering sector to optimize monoclonal antibody efficacy and specificity; Advances in molecular antibody engineering. INSET: Engineering Antibodies the Old-Fashioned Way.

  • Engineered Soluble Mimics Could Pave Way to Screen for GPCR Drugs. Holland-Moritz, Pam // Drug Discovery & Development;Aug2003, Vol. 6 Issue 8, p21 

    Reports on the successful engineering of a soluble mimic of rhodopsin, the visual photoreceptor from the rod cells of the retina. Importance in opening the possibility for therapeutics based on high-resolution structural data for rhodopsin and other members of the membrane protein group known...

  • PIPELINE.  // Nurse Practitioners Prescribing Reference;Summer2011, Vol. 18 Issue 2, pA-23 

    The article offers information on several drugs that are used for treating various diseases and are undergoing Phase 3 clinical trials including Lixisenatide peptide-1 agonist from sanofi-aventis, AMR101 omega-3 fatty acid from Amarin, and VY-770 from Vertex.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics